Dimensional Fund Advisors LP reduced its position in shares of LivaNova PLC (NASDAQ:LIVN) by 20.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 739,502 shares of the company’s stock after selling 186,821 shares during the period. Dimensional Fund Advisors LP owned approximately 1.52% of LivaNova worth $67,638,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Teachers Advisors LLC grew its stake in shares of LivaNova by 96.1% in the third quarter. Teachers Advisors LLC now owns 206,592 shares of the company’s stock worth $25,611,000 after purchasing an additional 101,262 shares during the last quarter. Emerald Mutual Fund Advisers Trust acquired a new position in shares of LivaNova during the fourth quarter valued at about $7,510,000. Prudential Financial Inc. raised its holdings in shares of LivaNova by 66.8% during the fourth quarter. Prudential Financial Inc. now owns 159,407 shares of the company’s stock valued at $14,581,000 after purchasing an additional 63,847 shares during the period. South Dakota Investment Council acquired a new position in shares of LivaNova during the fourth quarter valued at about $110,000. Finally, Texas Permanent School Fund raised its holdings in shares of LivaNova by 4.2% during the fourth quarter. Texas Permanent School Fund now owns 31,859 shares of the company’s stock valued at $2,914,000 after purchasing an additional 1,285 shares during the period. Institutional investors and hedge funds own 84.40% of the company’s stock.
LIVN traded down $0.46 on Friday, hitting $71.93. The company’s stock had a trading volume of 245,929 shares, compared to its average volume of 336,715. The company has a market cap of $3.57 billion, a PE ratio of 22.69, a price-to-earnings-growth ratio of 3.11 and a beta of 0.61. LivaNova PLC has a 12 month low of $64.80 and a 12 month high of $131.54. The company has a current ratio of 0.87, a quick ratio of 0.61 and a debt-to-equity ratio of 0.13.
In other news, CEO Damien Mcdonald sold 1,000 shares of the firm’s stock in a transaction on Wednesday, June 5th. The shares were sold at an average price of $73.58, for a total transaction of $73,580.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Alfred J. Novak sold 1,300 shares of the firm’s stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $70.63, for a total transaction of $91,819.00. The disclosure for this sale can be found here. Corporate insiders own 0.41% of the company’s stock.
A number of equities research analysts recently weighed in on the stock. BidaskClub lowered shares of LivaNova from a “buy” rating to a “hold” rating in a report on Friday. Needham & Company LLC restated a “buy” rating and issued a $87.00 target price on shares of LivaNova in a report on Tuesday, May 28th. BTIG Research reaffirmed a “hold” rating on shares of LivaNova in a research report on Thursday, May 2nd. Piper Jaffray Companies reduced their price objective on shares of LivaNova from $120.00 to $90.00 and set an “in-line” rating for the company in a research report on Wednesday, May 1st. Finally, Zacks Investment Research downgraded shares of LivaNova from a “hold” rating to a “sell” rating in a research report on Wednesday, May 1st. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $106.40.
ILLEGAL ACTIVITY NOTICE: This story was first reported by Rockland Register and is the sole property of of Rockland Register. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://rocklandregister.com/2019/06/15/livanova-plc-livn-shares-sold-by-dimensional-fund-advisors-lp.html.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.
Featured Article: Understanding Price to Earnings Ratio (PE)
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.